Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Wed, 03.08.2022
Formycon AG
Press Release // August 3, 2022
U.S. Food and Drug Administration (FDA) approved FYB201/CIMERLITM1 (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®2
CIMERLI™ is the only biosimilar approved for all five Lucentis® indications
Commercially available in 0.3 mg and 0.5 mg dosages
U.S. commercial launch by [ … ]
Wed, 03.08.2022
Formycon AG
Press Release // August 3, 2022
U.S. Food and Drug Administration (FDA) approved FYB201/CIMERLITM1 (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®2
CIMERLI™ is the only biosimilar approved for all five Lucentis® indications
Commercially available in 0.3 mg and 0.5 mg dosages
U.S. commercial launch by [ … ]
Wed, 03.08.2022
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 3, 2022
Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the U.S. Food [ … ]
Wed, 03.08.2022
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 3, 2022
Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the U.S. Food [ … ]
Fri, 01.07.2022
Formycon AG
Press Release // July 1, 2022
Formycon Reports on Virtual Annual General Meeting 2022
Shareholders approve all items on the agenda
Supervisory Board and Management Board ratified by a large majority
Dr. Thomas Strüngmann elected to the Supervisory Board with 99,99 %
Introduction of the new Management Board members Nicola Mikulcik an [ … ]
Fri, 01.07.2022
Formycon AG
Press Release // July 1, 2022
Formycon Reports on Virtual Annual General Meeting 2022
Shareholders approve all items on the agenda
Supervisory Board and Management Board ratified by a large majority
Dr. Thomas Strüngmann elected to the Supervisory Board with 99,99 %
Introduction of the new Management Board members Nicola Mikulcik an [ … ]
Tue, 28.06.2022
Formycon AG
Press Release // June 28, 2022
Formycon AG announces amendment to the proposal for election of a Supervisory Board member (agenda item 9) in the context of the Annual General Meeting on June 30, 2022
Munich – Based on the resolution of the Supervisory Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) dated June 27, 2022, the election proposa [ … ]
Tue, 28.06.2022
Formycon AG
Press Release // June 28, 2022
Formycon AG announces amendment to the proposal for election of a Supervisory Board member (agenda item 9) in the context of the Annual General Meeting on June 30, 2022
Munich – Based on the resolution of the Supervisory Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) dated June 27, 2022, the election proposa [ … ]
Fri, 24.06.2022
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // June 24, 2022
FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG ("Bioeq") announce that [ … ]
Tue, 21.06.2022
Formycon AG
Press Release // June 21, 2022
Formycon Reports First Quarter 2022 Financial Results and Announces Development Start of two New Biosimilar Candidates FYB208 and FYB209
- Sales and other earnings total EUR 8.2 million
- EBITDA is EUR -4.0 million as planned
- EBIT and net result in line with expectations at around EUR -4.3 million each
- Refere [ … ]